 ST. GALLEN, Switzerland UNIONDALE, NY--BUSINESS WIRE--Regulatory News: Vifor Pharma and Angion Biomedica Corp. NASDAQ: ANGN, today announced completion of enrollment for Angions AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury CSA-AKI. This indication is part of the ANG-3777 license agreement both parties signed in November 2020. CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of p 